Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sanofi - American Depositary Shares (NQ:SNY)

48.04 +0.05 (+0.10%)
Streaming Delayed Price Updated: 10:44 AM EST, Dec 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
39 40 Next >
News headline image
Sanofi Barrels Into Liver Disease Space With $1.7 Billion Takeover Of Inhibrx ↗
The company is buying Inhibrx, which is working on a treatment for alpha-1 antitrypsin deficiency. 
Via Investor's Business Daily
News headline image
French Drugmaker Sanofi Agrees To Buy Inhibrx's Candidate For Rare Genetic Indication, For About $2.2B ↗
Sanofi's strategic acquisition of Inhibrx's INBRX-101, a alpha-1 antitrypsin therapy in a registrational trial. Learn about the $2.2B merger details and Inhibrx Biosciences' spin-off. Closing expected... 
Via Benzinga
News headline image
Olympic Sponsor Sanofi Makes Major Play In Rare Disease Arena $2.2 Billion Acquisition Of Inhibrx Project ↗
Following the acquisition, New Inhibrx will continue to operate under the "Inhibrx" name, with Mark Lappe as Chairman and CEO. 
Via Benzinga
News headline image
Aclaris Therapeutics' ATI-1777 Faces Uphill Battle In Atopic Dermatitis Treatment Landscape, Analyst Downgrades ↗
HC Wainwright downgrades Aclaris Therapeutics post Phase 2b results of ATI-1777 for atopic dermatitis. Analyzing efficacy, commercial prospects, and competitive landscape. 
Via Benzinga
News headline image
Time to buy these 3 healthcare companies that raised revenue guidance?
The new year brings a clean slate heading into the fourth-quarter earnings season. Check out a few companies that have raised revenue guidance. 
Via MarketBeat
News headline image
Why NASDAQ:SNY is a Top Pick for Dividend Investors. ↗
Analyzing SANOFI-ADR (NASDAQ:SNY)'s Dividend Potential. 
Via Chartmill
News headline image
Looking Into Sanofi's Recent Short Interest ↗
 
Via Benzinga
News headline image
Why NASDAQ:SNY provides a good dividend, while having solid fundamentals. ↗
Why SANOFI-ADR (NASDAQ:SNY) provides a good dividend, while having solid fundamentals. 
Via Chartmill
News headline image
Why Big Pharma Led By Merck, Sanofi, Teva Are Pouring Billions Into A New Immunology Space ↗
The companies are working on blocking TL1A, a protein tied to inflammatory bowel disease. 
Via Investor's Business Daily
News headline image
Sanofi's Olympic Endeavor: Leap Into Olympic Sponsorship Signals Cultural Transformation ↗
French pharmaceutical giant Sanofi SA (NASDAQ: SNY) is making an unconventional stride by sponsoring the 2024 Olympic Games in Paris in an effort to rejuvenate the company's image, attract a younger... 
Via Benzinga
News headline image
Kymera Therapeutics Stock Whiplash: Shares Soar, Then Tumble After $275 Million Offering ↗
Shares soared and then tumbled Friday after the company offered $275 million in public shares. 
Via Investor's Business Daily
News headline image
More Than 140 Drug Brands Will Have Their Prices Hiked Heading Into 2024 ↗
More than 140 brands of drugs are going to see their prices hiked heading into the new year 
Via Talk Markets
News headline image
China Approves AstraZeneca-Sanofi's Respiratory Syncytial Virus Drug To Prevent Infection In Infants ↗
Tuesday, China's National Medical Products Administration approved AstraZeneca Plc (NASD 
Via Benzinga
News headline image
Expensive Drugs For Americans In 2024? Drugmakers Including Pfizer, Sanofi Mull Price Increase In January ↗
Just as large pharma companies prepare a showdown with Medicare's newfound power to negotiate down drug prices, several major drug companies are reportedly gearing up to implement price increases on... 
Via Benzinga
News headline image
NASDAQ:SNY is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. ↗
SANOFI-ADR (NASDAQ:SNY): good value for what you're paying. 
Via Chartmill
News headline image
Why First Wave BioPharma Shares Are Skyrocketing Today ↗
First Wave BioPharma, Inc. (NASDAQ: FWBI) shares are skyrocketing Wednesday after the company entered a non-binding term sheet to sell its Niclosamide program for the treatment of  
Via Benzinga
News headline image
Why Is Eye Disease Related Gene Therapy Focused MeiraGTx Stock Soaring Today? ↗
MeiraGTx Holdings plc (NASDAQ: MGTX) on Thursday announced an asset purchase agreement with Janssen Pharmaceuticals Inc, a Johnson & Johnson (NYSE: JNJ) compan 
Via Benzinga
News headline image
European Drugmaker Sanofi Ends Tusamitamab Ravtansine Lung Cancer Program After Disappointing Data ↗
Sanofi SA (NASDAQ: SNY) is discontinuing the global clinical development pr 
Via Benzinga
News headline image
First Wave BioPharma To Acquire ImmunogenX To Bolster Gastrointestinal-Focused Pipeline ↗
First Wave BioPharma Inc (NASDAQ: FWBI) has signed a non-binding term sheet to acquire ImmunogenX in an all-stock transaction with the combined company focused on advancing a pipeline for... 
Via Benzinga
News headline image
7 Undervalued Biotech Stocks That are Flying Under the Clinical Radar ↗
While the broader healthcare sector offers myriad opportunities, these undervalued biotech picks could offer robust upside. 
Via InvestorPlace
News headline image
It's Almost 2024: 3 Top Stocks to Buy Before the New Year ↗
You can pick these players up for a great price right now. 
Via The Motley Fool
News headline image
French Drugmaker Sanofi Secures European Medicines Agency's Positive Opinion For Sleeping Sickness Treatment ↗
Sanofi SA (NASDAQ: SNY), DNDi, and the HAT-r-ACC consortium  
Via Benzinga
News headline image
3 Stocks to Buy Before 2024 That Can Set You Up For Life ↗
These stocks are still relatively cheap, but don't expect them to stay that way for long. 
Via The Motley Fool
News headline image
French Pharma Giant Sanofi Drops Rare Disease Drug Pact As Federal Trade Commission Puts Antitrust Obstacle ↗
Sanofi SA (NASDAQ: SNY) said it is terminating the licensing agreement for Maze Therapeutics Inc.'s treatment for a rare genetic disorder after the Federal Trade Commission (FTC)  
Via Benzinga
News headline image
Vanda Pharmaceuticals Acquires Rights To Multiple Sclerosis Drug From Johnson & Johnson's Company ↗
Vanda Pharmaceuticals Inc (NASDAQ: VNDA) has acquired U.S. 
Via Benzinga
News headline image
Sanofi Lays Out Ambitious Plans To Bolster Its Pipeline, Highlights 12 Blockbuster Opportunities ↗
Sanofi SA (NASDAQ: SNY) says it has 12 drugs in development with a blockbus 
Via Benzinga
News headline image
IGM Biosciences Increases Focus On Autoimmune Diseases, Stops All Blood Cancer-Related Studies ↗
IGM Biosciences Inc (NASDAQ: IGMS) said it will focus on two strategic areas: treating colorectal cancer using IgM death receptor 5 (DR5) agonist antibodies and treating autoimmune diseases using IgM... 
Via Benzinga
News headline image
Merck Germany's Two Pivotal Trials Flunk In Multiple Sclerosis ↗
Merck KGaA (OTC: MKGAF) (OTC:  
Via Benzinga
News headline image
Don't overlook NASDAQ:SNY—it's a hidden gem with strong fundamentals and an attractive price tag. ↗
SANOFI-ADR (NASDAQ:SNY) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. 
Via Chartmill
News headline image
Investor Demand for Clarity Grows Amid Sanofi's Strategic R&D Shift ↗
Sanofi SA's (NASDAQ: SNY) CEO, Paul Hudson, is confronting mounting investor pressure as shareholders seek concrete details about the company's expanded R&D budget.  
Via Benzinga
< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
39 40 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.